Medidata Solutions (NASDAQ:MDSO) has been given a $86.00 price objective by analysts at Royal Bank of Canada in a research report issued on Friday. The brokerage presently has a “buy” rating on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 22.75% from the stock’s current price.

Other analysts have also issued reports about the stock. BidaskClub upgraded shares of Medidata Solutions from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 16th. Needham & Company LLC lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, July 25th. ValuEngine upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. Piper Jaffray Companies reduced their price target on shares of Medidata Solutions from $96.00 to $93.00 in a research note on Thursday. Finally, Morgan Stanley set a $84.00 price target on shares of Medidata Solutions and gave the stock a “hold” rating in a research note on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company’s stock. Medidata Solutions currently has an average rating of “Buy” and an average price target of $85.25.

NASDAQ:MDSO opened at $70.06 on Friday. The stock has a market cap of $4.18 billion, a price-to-earnings ratio of 82.42, a PEG ratio of 4.40 and a beta of 1.44. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.52 and a quick ratio of 1.41. Medidata Solutions has a fifty-two week low of $59.60 and a fifty-two week high of $88.87.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, October 18th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.06. Medidata Solutions had a net margin of 8.43% and a return on equity of 10.70%. The firm had revenue of $163.41 million during the quarter, compared to analyst estimates of $162.09 million. During the same period in the previous year, the business posted $0.33 earnings per share. The business’s revenue for the quarter was up 17.6% on a year-over-year basis. Equities research analysts expect that Medidata Solutions will post 0.8 earnings per share for the current year.

In related news, Director Robert Taylor sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 31st. The shares were sold at an average price of $73.05, for a total value of $365,250.00. Following the transaction, the director now owns 44,036 shares of the company’s stock, valued at $3,216,829.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael I. Otner sold 9,288 shares of the firm’s stock in a transaction that occurred on Tuesday, July 24th. The stock was sold at an average price of $81.03, for a total transaction of $752,606.64. The disclosure for this sale can be found here. In the last three months, insiders sold 26,788 shares of company stock worth $2,069,857. 4.70% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Medidata Solutions by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 130,588 shares of the company’s stock worth $8,202,000 after buying an additional 663 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Medidata Solutions by 3.0% during the second quarter. Oregon Public Employees Retirement Fund now owns 22,786 shares of the company’s stock valued at $1,836,000 after purchasing an additional 666 shares in the last quarter. Front Row Advisors LLC lifted its holdings in Medidata Solutions by 6.1% during the second quarter. Front Row Advisors LLC now owns 12,623 shares of the company’s stock valued at $980,000 after purchasing an additional 725 shares in the last quarter. Polen Capital Management LLC lifted its holdings in Medidata Solutions by 12.2% during the second quarter. Polen Capital Management LLC now owns 7,413 shares of the company’s stock valued at $597,000 after purchasing an additional 806 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY lifted its holdings in Medidata Solutions by 3.0% during the second quarter. Metropolitan Life Insurance Co. NY now owns 34,464 shares of the company’s stock valued at $2,776,000 after purchasing an additional 993 shares in the last quarter.

About Medidata Solutions

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Recommended Story: Asset Allocation and Your Retirement

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.